{"transactions":[{"id":2244766,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":126562,"kind":"person","name":"Dalton Barbara","position":1,"cik":"0001591318","reported_name":"Dalton Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-04T00:20:32.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant."}],"balance_after":8500,"derivative":{"exercise_price":1.07,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-22-034389","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919122034389/doc4.xml","form_type":"4"}},{"id":2647626,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":126562,"kind":"person","name":"Dalton Barbara","position":1,"cik":"0001591318","reported_name":"Dalton Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T23:07:23.000Z","date":"2021-06-29","kind":"grant","acquired":true,"shares":7728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant."}],"balance_after":7728,"derivative":{"exercise_price":8.12,"expiration_date":"2031-06-28","underlying":"Common Stock","underlying_shares":7728},"source":{"system":"sec-edgar","filing":"0001209191-21-044600","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919121044600/doc4.xml","form_type":"4"}},{"id":3208938,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":126562,"kind":"person","name":"Dalton Barbara","position":1,"cik":"0001591318","reported_name":"Dalton Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-03-16T21:18:16.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":15457,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in three equal installments on March 16, 2021, 2022 and 2023."}],"balance_after":15457,"derivative":{"exercise_price":16,"expiration_date":"2030-03-15","underlying":"Common Stock","underlying_shares":15457},"source":{"system":"sec-edgar","filing":"0000899243-20-008496","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008496/doc4.xml","form_type":"4"}},{"id":3208937,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":126562,"kind":"person","name":"Dalton Barbara","position":1,"cik":"0001591318","reported_name":"Dalton Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-16T21:18:16.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":1894444,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entities affiliated with Pfizer Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is Vice President of Venture Capital at Pfizer, Inc., an affiliate of Pfizer Ventures (US) LLC.  The reporting person disclaims beneficial ownership of the shares owned by the entities affiliated with Pfizer Ventures (US) LLC except to the extent of her pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":300752},"source":{"system":"sec-edgar","filing":"0000899243-20-008496","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008496/doc4.xml","form_type":"4"}},{"id":3208936,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":126562,"kind":"person","name":"Dalton Barbara","position":1,"cik":"0001591318","reported_name":"Dalton Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-03-16T21:18:16.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":5470492,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entities affiliated with Pfizer Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 16, 2020, the Issuer's Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 16, 2020, the Issuer's Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 16, 2020, the Issuer's Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is Vice President of Venture Capital at Pfizer, Inc., an affiliate of Pfizer Ventures (US) LLC.  The reporting person disclaims beneficial ownership of the shares owned by the entities affiliated with Pfizer Ventures (US) LLC except to the extent of her pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":868467},"source":{"system":"sec-edgar","filing":"0000899243-20-008496","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008496/doc4.xml","form_type":"4"}},{"id":3208935,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":126562,"kind":"person","name":"Dalton Barbara","position":1,"cik":"0001591318","reported_name":"Dalton Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-03-16T21:18:16.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":478749,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entities affiliated with Pfizer Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On March 16, 2020, the Issuer's Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 16, 2020, the Issuer's Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 16, 2020, the Issuer's Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is Vice President of Venture Capital at Pfizer, Inc., an affiliate of Pfizer Ventures (US) LLC.  The reporting person disclaims beneficial ownership of the shares owned by the entities affiliated with Pfizer Ventures (US) LLC except to the extent of her pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":76003},"source":{"system":"sec-edgar","filing":"0000899243-20-008496","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008496/doc4.xml","form_type":"4"}},{"id":3208934,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":126562,"kind":"person","name":"Dalton Barbara","position":1,"cik":"0001591318","reported_name":"Dalton Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T21:18:16.000Z","date":"2020-03-16","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":false,"nature":"By entities affiliated with Pfizer Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is Vice President of Venture Capital at Pfizer, Inc., an affiliate of Pfizer Ventures (US) LLC.  The reporting person disclaims beneficial ownership of the shares owned by the entities affiliated with Pfizer Ventures (US) LLC except to the extent of her pecuniary interest therein."}],"balance_after":1557722,"source":{"system":"sec-edgar","filing":"0000899243-20-008496","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008496/doc4.xml","form_type":"4"}},{"id":3208933,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":126562,"kind":"person","name":"Dalton Barbara","position":1,"cik":"0001591318","reported_name":"Dalton Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T21:18:16.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":1245222,"ownership":{"direct":false,"nature":"By entities affiliated with Pfizer Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 16, 2020, the Issuer's Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is Vice President of Venture Capital at Pfizer, Inc., an affiliate of Pfizer Ventures (US) LLC.  The reporting person disclaims beneficial ownership of the shares owned by the entities affiliated with Pfizer Ventures (US) LLC except to the extent of her pecuniary interest therein."}],"balance_after":1245222,"source":{"system":"sec-edgar","filing":"0000899243-20-008496","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008496/doc4.xml","form_type":"4"}}]}